Strategic Acquisition As a subsidiary of WIRB-Copernicus Group since 2019, WCG Analgesic Solutions benefits from integration into a global network of clinical research services, presenting cross-selling opportunities for expanded trial management and consulting.

Pain Management Focus Specializing in pain treatment trials with a track record of expertise and innovation, the company is well-positioned to address the growing demand for opioid alternatives and pain relief solutions, appealing to clients seeking cutting-edge therapies.

Technology Adoption Utilizing a tech stack that includes MySQL, PHP, and specialized monitoring tools, WCG Analgesic Solutions emphasizes data-driven clinical trial processes, opening doors for partnerships around advanced trial monitoring and digital tools.

Growth Potential With revenues estimated between 1 million and 10 million dollars and a lean team of up to 50 employees, the company offers significant opportunity for targeted services that support scaling clinical trial operations and regulatory compliance.

Leadership and Expertise Led by founder and Chief Scientific Officer Nathaniel P. Katz, the company’s focus on pain research and clinical trial excellence positions it as a valuable collaborator for organizations seeking specialized scientific guidance and innovative trial strategies.